Pharmaron Beijing Co., Ltd. (FRA:17Q1)

Market Cap	6.50B
Revenue (ttm)	1.62B
Net Income (ttm)	181.07M
Shares Out	n/a
EPS (ttm)	0.10
PE Ratio	35.90
Forward PE	24.52
Dividend	0.02 (1.12%)
Ex-Dividend Date	Jul 4, 2025

Volume	n/a
Average Volume	n/a
Open	2.480
Previous Close	2.460
Day's Range	2.480 - 2.480
52-Week Range	1.310 - 3.240
Beta	n/a
RSI	60.50
Earnings Date	Mar 31, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotide...

• Industry: Commercial Physical and Biological Research
• Founded: 2004
• Employees: 21,370
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 17Q1

Financial Performance

In 2024, Pharmaron Beijing's revenue was 12.28 billion, an increase of 6.39% compared to the previous year's 11.54 billion. Earnings were 1.79 billion, an increase of 12.01%.

Financial numbers in CNY